Searched for
USA PRESCRIPTION PORTFOLIO
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- For investors with ability to buy businesses, not just stocks: 10 stocks from different sectors which increase probability of wealth creationHow many air conditioners/mobile phones were sold in India 15 years back? How many are sold today? Do tariffs make any difference to a hyde...
- Healthcare stocks: Better to own a collection? 16 stocks from different segments with upside potential of 10 to 35% in 1 yearBefore you read on, be clear about one thing. The stocks on our list today are expensive in terms of valuations and may well witness correc...
- Pharma stocks: Moving from ‘What if’ to ‘Maybe not’. 8 pharma stocks, 3 with upside potential above 22%; others not so high, but…There are two ways to look at the hope which the street is reflecting when it comes to a possible India-US tariff deal. One, it will bring ...
- Pharma sector: Reasons to look at it beyond the tariff exemption. 7 pharma stocks with an upside potential of up to 43%Along with semiconductors, electronics and IT, pharma is another sector exempt from the Trump tariffs. Still, as the broader indices declin...
- Suited for the long term, even with headwinds: 8 stocks from healthcare & pharma sectors with upside potential of up to 39%How to define a “defensive sector”? One where earnings increase in a secular manner and stocks have lower probability of witnessing a sharp...
- They fall, you catch. One might be a winner in the long term: 8 pharma stocks with upside potential of over 35%Given that the headlines are dominated by what is happening at the border, the street may be forgiven for not noting developments that matt...
- Pharma stocks: With headwinds of uncertainty over, will they outperform? 7 stocks with an upside potential of up to 43%When it is Trump, logic usually flies out of the window. There is, indeed, little that is logical about the reciprocal tariffs he has annou...
- Pharma: Stay bullish, but hedge to avoid mistake of selling due to deadline. 7 stocks with upside potential of up to 50%While Democrats are better known to push for lower drug prices in the US, in recent times even Republicans are talking about keeping the co...
- Necessary pill for portfolio during volatility and Trump tariff wars: 8 pharma stocks with an upside potential of up to 48%Let’s accept the fact that we are likely to be dealing with volatility for the next four years. Both in the real world and in the global an...
- Decline in rupee: Besides IT, there are other winners as well; 9 pharma stocks with an upside potential of up to 40%The relationship between a decline in the rupee and better margins for IT companies is well known. What is not discussed much is that pharm...
- A Trump tariff tantrum-proof sector? 8 stocks from pharma sector, where Democrats and Republicans are in agreement, with an upside potential of up to 34% in 1 yearWhen Donald Trump is back in the saddle, one thing is certain: Tariff wars. Yes, China will be the biggest target. But for all those who th...
- Glenmark launches generic glaucoma treatment ophthalmic solutionGlenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z, a glaucoma treatment, called Travoprost ophthalmic solution (0...
- Corrections are opportunities, if you enter the right sector and stocks: 5 stocks from pharma sector with an upside potential of up to 32%At a time when the Nifty and Sensex are trading with cuts in excess of 1%, talking of buying stocks may not appear quite right. But correct...
- These healthcare and pharma stocks may deliver more than 20% in one yearCheck out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focu...
- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- Nifty healthcare index stocks; Staying bullish on select pharma and hospitalsWhile they clubbed together, the operating matrix of a pharma company making drugs and hospital and a diagnostic company are very different...
- Dr Reddy's to acquire Mayne Pharma US generic portfolio for $105 millionUnder the terms of the agreement, Dr. Reddy’s will acquire the portfolio for an upfront payment of $90 million in cash, contingent payments...
Load More
